In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Lilly Out, Amylin’s Future Is Tied To Bydureon

Executive Summary

With the unwinding of its once-lucrative nine-year partnership with Eli Lilly, Amylin Pharmaceuticals now carries all the risk – and all the reward – of its exenatide franchise for diabetes. With sole ownership of its exenatide franchise, Amlyin now has the freedom to seek a lucrative partnership or opt to sell the company outright to a large pharma seeking an edge in a growing diabetes market.

You may also be interested in...

AstraZeneca Hopes Bydureon Pen Will Rewrite GLP-1 Story

FDA approved an easier-to-use pen version of Bydureon for the treatment of type 2 diabetes, but AstraZeneca will need to move quickly and effectively with the launch if it is to establish the brand before other long-acting GLP-1’s enter the market.

Biopharma Quarterly Deal Statistics, Q1 2012

Biopharma financing totaled $3.7 billion in Q1 2012, $1 billion more than the previous quarter. A total of 22 M&As – with a potential value of $9.28 billion – were completed. Acquisitions of private biotechs structured with earn-outs were a highlight. About a quarter of the alliances involved Big Pharmas, with GlaxoSmithKline and Novartis taking the lead.

Icahn Turns Up The Heat On Amylin, Urges Board To Sell

The activist investor, previously involved in buyouts at ImClone, Biogen Idec and Elan, as well as a proxy fight at Genzyme, scolds Amylin’s board for lack of transparency on purported Bristol offer and asserts the biotech is not positioned to maximize the market potential of Bydureon.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts